Keeshia Muhammad
Keeshia Muhammad
Executive Director, Marketing, Teva Specialty Pharmaceuticals
MAKES PHARMA A BETTER PLACE: The Healthcare Businesswomen's Association
REWARD: Standing ovations for marketing teams from the sales force
Keeshia Muhammad says much of what you need to know about co-promotion you learned in kindergarten. "It's about collaborating with people, with the foundation of integrity, trust, and respect. Hidden agendas ultimately tarnish relationships as you start to build a team."
Keeshia Muhammad
And she should know. Muhammad worked on the Merck/Schering-Plough joint venture for Zetia and Vytorin, maintained Altana's voice in its COPD hopeful PDE-4 inhibitor partnership with Pfizer, and managed Altana's co-promotion of Alvesco with Sanofi-Aventis. While she may have played nice in the past, Muhammad is showing an edge in her new role. Under her leadership, Teva's flagship asthma brand ProAir HFA has nearly doubled its market share to 60 percent. So how does she do it? "I bring passion and energy to the table," she says. "I always have people asking me, 'Can I have a dose of that?'"
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.